FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
J&J beats in Q4 with in line guidance; so why is its stock falling?
Johnson & Johnson (NYSE:JNJ) fell ~3% in early trading on Wednesday, marking its biggest intraday drop since July 2023, even as the healthcare giant posted better-than-expected financials for Q4 2024 ...
Investor's Business Daily on MSN1d
J&J Skids After Dow Giant Beat Earnings Views, But 'Prudent' Guidance Disappoints
Johnson & Johnson stock fell slightly early Wednesday after the health care titan reported adjusted earnings of $2.04 per share on $22.5 in fourth-quarter sales. Please watch the video at ...
J&J Reports Strong Revenue and Profit but Faces Challenges in 2025
Johnson & Johnson reported better-than-expected quarterly revenue and profit on higher sales of cancer drugs and some medical devices. But shares slipped 3.2% to $143.35 in Wednesday morning trading, ...
J.J. McCarthy returns to on-field training: What it means for Vikings’ QB room
“I’m very excited about where J.J. is at,” Vikings head coach Kevin O’Connell said in an end-of-season press conference.